Progress and prospects: gene therapy for inherited immunodeficiencies

Area of Science:

• Immunology
• Genetics
• Hematology

Background:

• Hematopoietic stem cell transplantation (HSCT) is a standard treatment for primary immunodeficiencies (PID).
• Gene therapy presents a viable alternative for PID patients lacking suitable HLA-matched donors.
• Specific PID like SCID-X1, ADA-SCID, X-CGD, and WAS are key targets for gene therapy.

Purpose of the Study:

• To review the role and advancements of gene therapy in treating primary immunodeficiencies (PID).
• To discuss the successes and challenges, including adverse events, associated with gene therapy for PID.
• To highlight the development of next-generation vectors for improved gene therapy safety and efficacy.

Main Methods:

• Review of clinical outcomes and safety profiles of gene therapy for PID.
• Analysis of retroviral vector integration patterns and associated adverse events.
• Development and preclinical evaluation of novel self-inactivating retroviral and lentiviral vectors.

Main Results:

• Gene therapy has shown success in treating specific PIDs by offering corrected cells a selective advantage and avoiding graft-versus-host disease.
• Chemotherapy pre-conditioning aids engraftment of gene-corrected cells.
• Adverse events have been identified, prompting detailed vector integration profiling.

Conclusions:

• Gene therapy is a crucial alternative for PID patients without HLA-matched donors.
• Ongoing research focuses on enhancing gene therapy safety through advanced vector design.
• Next-generation retroviral and lentiviral vectors are nearing clinical application for PID treatment.